{"nctId":"NCT01251276","briefTitle":"Hepatitis B Challenge Dose in Adults (V232-059-10)","startDateStruct":{"date":"2010-11-30","type":"ACTUAL"},"conditions":["Hepatitis B"],"count":204,"armGroups":[{"label":"Modified Process Hepatitis B Vaccine in Base Study","type":"EXPERIMENTAL","interventionNames":["Biological: Modified Process Hepatitis B Vaccine"]},{"label":"ENGERIX-Bâ„¢ Vaccine in Base Study","type":"EXPERIMENTAL","interventionNames":["Biological: Modified Process Hepatitis B Vaccine"]}],"interventions":[{"name":"Modified Process Hepatitis B Vaccine","otherNames":["HBVaxPro"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In general good health based on a medical history.\n* Received 3 doses of an Hepatitis B vaccine in Base Study V232-059, NCT00440531 at least 2 years prior to enrollment in this study.\n\nExclusion Criteria:\n\n* Known history of previous Hepatitis B infection.\n* History of vaccination with any Hepatitis B vaccine within the last 2 years.\n* History of febrile illness.\n* Known or suspected hypersensitivity to any component of HBVaxPro.\n* Receipt of medication / vaccine that may interfere with study assessments.\n* Known or suspected immune impairment.\n* Pregnant women and nursing mothers.","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Seroresponders Before and After the Challenge Vaccination","description":"A seroresponder was a participant with an anti-hepatitis B surface antibody titer \\>=10 milli Merck U/mL. The percentage of seroresponders was assessed before and after the challenge dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null},{"groupId":"OG001","value":"58.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.2","spread":null},{"groupId":"OG001","value":"88.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With One or More Adverse Experiences","description":"An adverse experience is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an adverse experience. The percentage of participants with one or more adverse experiences was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"45.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Discontinued the Study Due to an Adverse Experience","description":"The percentage of participants who discontinued the study due to an adverse experience was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With One or More Injection-site Adverse Experiences","description":"The percentage of participants with one or more injection-site adverse experiences was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null},{"groupId":"OG001","value":"29.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With One or More Systemic Adverse Experiences","description":"The percentage of participants with one or more systemic adverse experiences was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"28.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With One or More Serious Adverse Experiences","description":"A serious adverse experience is an adverse experience that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or may jeopardize the participant and may require medical or surgical intervention. The percentage of participants with one or more serious adverse experiences was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":96},"commonTop":["Injection-site pain","Injection-site erythema","Injection-site swelling"]}}}